IoM Committee To Hear CDER, PhRMA Perspectives On Drug Safety System
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Acting Director Galson will outline FDA's charge to the Institute of Medicine drug safety committee, while PhRMA Regulatory Affairs VP Goldhammer will discuss industry perspectives at the first meeting of the ad hoc committee June 8.
You may also be interested in...
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: